EP1222933A1 - Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt - Google Patents
Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt Download PDFInfo
- Publication number
- EP1222933A1 EP1222933A1 EP01200123A EP01200123A EP1222933A1 EP 1222933 A1 EP1222933 A1 EP 1222933A1 EP 01200123 A EP01200123 A EP 01200123A EP 01200123 A EP01200123 A EP 01200123A EP 1222933 A1 EP1222933 A1 EP 1222933A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- wnt
- cell
- pathway
- compound according
- anyone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004072 lung Anatomy 0.000 title claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 32
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 32
- 210000002588 alveolar type II cell Anatomy 0.000 claims abstract description 31
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 210000005265 lung cell Anatomy 0.000 claims abstract description 17
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 17
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 16
- 201000005202 lung cancer Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 12
- 206010014561 Emphysema Diseases 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 10
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 8
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 54
- 230000014509 gene expression Effects 0.000 claims description 39
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 claims description 33
- 102100030053 Secreted frizzled-related protein 3 Human genes 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 16
- 230000035755 proliferation Effects 0.000 claims description 15
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 claims description 11
- 102000043043 TCF/LEF family Human genes 0.000 claims description 11
- 108091084789 TCF/LEF family Proteins 0.000 claims description 11
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 10
- 102000040945 Transcription factor Human genes 0.000 claims description 9
- 108091023040 Transcription factor Proteins 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 claims description 8
- 108010048992 Transcription Factor 4 Proteins 0.000 claims description 8
- 102100035097 Transcription factor 7-like 1 Human genes 0.000 claims description 8
- 108050005285 Transcription factor 7-like 1 Proteins 0.000 claims description 8
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims description 8
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 claims description 7
- 102100030054 Secreted frizzled-related protein 2 Human genes 0.000 claims description 7
- 108050007987 Secreted frizzled-related protein 2 Proteins 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 102100030052 Secreted frizzled-related protein 4 Human genes 0.000 claims description 6
- 108050008088 Secreted frizzled-related protein 4 Proteins 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 claims 1
- 108050007993 Secreted frizzled-related protein 1 Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 39
- 108020004999 messenger RNA Proteins 0.000 description 17
- 108050003627 Wnt Proteins 0.000 description 15
- 102000013814 Wnt Human genes 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241001529936 Murinae Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000007040 lung development Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 210000005239 tubule Anatomy 0.000 description 9
- 108060000903 Beta-catenin Proteins 0.000 description 8
- 102000015735 Beta-catenin Human genes 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 230000001605 fetal effect Effects 0.000 description 7
- 208000019693 Lung disease Diseases 0.000 description 6
- 102000000999 Secreted frizzled-related protein 1 Human genes 0.000 description 6
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 210000002383 alveolar type I cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 108050007990 Secreted frizzled-related protein 3 Proteins 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000002220 organoid Anatomy 0.000 description 3
- 210000001533 respiratory mucosa Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 2
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 2
- 102000000479 TCF Transcription Factors Human genes 0.000 description 2
- 108010016283 TCF Transcription Factors Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000005305 organ development Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- QLRRUWXMMVXORS-UHFFFAOYSA-N Augustine Natural products C12=CC=3OCOC=3C=C2CN2C3CC(OC)C4OC4C31CC2 QLRRUWXMMVXORS-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101710181403 Frizzled Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 230000007905 lung morphogenesis Effects 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000005126 pseudostratified columnar epithelium Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01200123A EP1222933A1 (fr) | 2001-01-15 | 2001-01-15 | Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt |
| CA002434431A CA2434431A1 (fr) | 2001-01-15 | 2002-01-15 | Formation et/ou la reduction de nouveaux tissus pulmonaires dans un poumon affecte |
| PCT/NL2002/000025 WO2002055109A2 (fr) | 2001-01-15 | 2002-01-15 | Formation et/ou la reduction de nouveaux tissus pulmonaires dans un poumon affecte |
| US10/250,954 US20040223952A1 (en) | 2001-01-15 | 2002-01-15 | Generation and/or reduction of new lung tissue in an affected lung |
| EP02710537A EP1351711A2 (fr) | 2001-01-15 | 2002-01-15 | Formation et/ou la reduction de nouveaux tissus pulmonaires dans un poumon affecte |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01200123A EP1222933A1 (fr) | 2001-01-15 | 2001-01-15 | Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1222933A1 true EP1222933A1 (fr) | 2002-07-17 |
Family
ID=8179748
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP01200123A Withdrawn EP1222933A1 (fr) | 2001-01-15 | 2001-01-15 | Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt |
| EP02710537A Withdrawn EP1351711A2 (fr) | 2001-01-15 | 2002-01-15 | Formation et/ou la reduction de nouveaux tissus pulmonaires dans un poumon affecte |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02710537A Withdrawn EP1351711A2 (fr) | 2001-01-15 | 2002-01-15 | Formation et/ou la reduction de nouveaux tissus pulmonaires dans un poumon affecte |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20040223952A1 (fr) |
| EP (2) | EP1222933A1 (fr) |
| CA (1) | CA2434431A1 (fr) |
| WO (1) | WO2002055109A2 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007090872A2 (fr) * | 2006-02-09 | 2007-08-16 | Novartis Ag | Agents de liaison de la proteine-4 apparentee a frizzled (sfrp-4) |
| EP2366432A1 (fr) | 2010-03-16 | 2011-09-21 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibiteurs de kinase 3 de synthèse de glycogène à utiliser dans les procédés thérapeutiques et procédé de criblage associé |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1548100A1 (fr) * | 2003-11-11 | 2005-06-29 | DeltaCell B.V. | Inhibition de la differéntiation des cellules souches, prolifération améliorée et induction sélective de l'apoptose par les facteurs de WNT |
| CN1981054A (zh) * | 2004-05-14 | 2007-06-13 | 加利福尼亚大学董事会 | 用抗wnt2单克隆抗体和sirna治疗癌症的方法 |
| US8198244B2 (en) | 2006-12-07 | 2012-06-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Regulation of skin characteristics by DICKKOPF1 (DKK1) |
| EP2450707B1 (fr) * | 2010-11-04 | 2016-04-27 | University of Pécs | Modèle de tissu de poumon |
| EP3524274A3 (fr) | 2009-07-15 | 2020-01-01 | Zhenglun Zhu | Gérer le traitement de troubles prolifératifs cellulaires en utilisant l'expression de hom-1 |
| KR101268478B1 (ko) | 2010-03-08 | 2013-06-04 | 한국원자력연구원 | Ｄｋｋ３ 발현 또는 활성 억제제를 함유하는 암 예방 및 치료용 조성물 |
| US10975357B2 (en) | 2017-06-27 | 2021-04-13 | Trustees Of Boston University | Methods and compositions related to differentiated lung cells |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998013493A2 (fr) * | 1996-09-24 | 1998-04-02 | Lxr Biotechnology, Inc. | Famille de genes codant les peptides lies a l'apoptose, peptides ainsi codes et leurs procedes d'utilisation |
| WO1998054325A1 (fr) * | 1997-05-29 | 1998-12-03 | The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services | Frp humaine et fragments de cette derniere et leurs utilisations |
| WO1999022000A1 (fr) * | 1997-10-27 | 1999-05-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Proteine inhibitrice de la voie de signalisation wnt |
| WO2000038709A1 (fr) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Traitement de troubles d'hyperproliferation a l'aide de caseine kinase i |
| WO2000052047A2 (fr) * | 1999-03-05 | 2000-09-08 | Millennium Pharmaceuticals, Inc. | Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations |
| WO2001019855A2 (fr) * | 1999-09-13 | 2001-03-22 | American Home Products Corporation | Compositions pharmaceutiques et modalite d'utilisation de proteine sfrp |
| WO2001044279A2 (fr) * | 1999-12-17 | 2001-06-21 | Chiron Corporation | Proteines de mammifere associees dishevelled |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004528A (en) * | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| US6066500A (en) * | 1999-06-25 | 2000-05-23 | Isis Pharmaceuticals Inc. | Antisense modulation of Beta catenin expression |
-
2001
- 2001-01-15 EP EP01200123A patent/EP1222933A1/fr not_active Withdrawn
-
2002
- 2002-01-15 CA CA002434431A patent/CA2434431A1/fr not_active Abandoned
- 2002-01-15 EP EP02710537A patent/EP1351711A2/fr not_active Withdrawn
- 2002-01-15 WO PCT/NL2002/000025 patent/WO2002055109A2/fr not_active Application Discontinuation
- 2002-01-15 US US10/250,954 patent/US20040223952A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998013493A2 (fr) * | 1996-09-24 | 1998-04-02 | Lxr Biotechnology, Inc. | Famille de genes codant les peptides lies a l'apoptose, peptides ainsi codes et leurs procedes d'utilisation |
| WO1998054325A1 (fr) * | 1997-05-29 | 1998-12-03 | The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services | Frp humaine et fragments de cette derniere et leurs utilisations |
| WO1999022000A1 (fr) * | 1997-10-27 | 1999-05-06 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Proteine inhibitrice de la voie de signalisation wnt |
| WO2000038709A1 (fr) * | 1998-12-31 | 2000-07-06 | Chiron Corporation | Traitement de troubles d'hyperproliferation a l'aide de caseine kinase i |
| WO2000052047A2 (fr) * | 1999-03-05 | 2000-09-08 | Millennium Pharmaceuticals, Inc. | Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations |
| WO2001019855A2 (fr) * | 1999-09-13 | 2001-03-22 | American Home Products Corporation | Compositions pharmaceutiques et modalite d'utilisation de proteine sfrp |
| WO2001044279A2 (fr) * | 1999-12-17 | 2001-06-21 | Chiron Corporation | Proteines de mammifere associees dishevelled |
Non-Patent Citations (10)
| Title |
|---|
| BARKER N., CLEVERS H.: "Catenins, Wnt signaling and cancer", BIOESSAYS, vol. 22, November 2000 (2000-11-01), pages 961 - 965, XP002174508 * |
| BIENZ M., CLEVERS H.: "Linking colorectal cancer to Wnt signaling", CELL, vol. 103, 13 October 2000 (2000-10-13), pages 311 - 320, XP002174510 * |
| CALVO, R. ET AL.: "Altered HOX and WNT7A expression in human lung cancer", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 23, 7 November 2000 (2000-11-07), pages 12776 - 12781, XP002174507 * |
| DENNIS S. ET AL: "A secreted Frizzled related protein, FrzA, selectively associates with Wnt-1 protein and regulates Wnt-1 signaling.", J. CELL. SCI., vol. 112, 1999, pages 3815 - 3820, XP002174506 * |
| DUMONTELLE J ET AL: "Inhibition of expression of the endogenous mammary oncogene Wnt-1 by antisense oligodeoxynucleotides", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 36, March 1995 (1995-03-01), pages 515, XP002147584, ISSN: 0197-016X * |
| GILBERT KA AND RANNELS DE: "From Limbs to Lungs: a Newt Perspective on Compensatory Lung Growth", NEWS PHYSIOL. SCI., vol. 14, December 1999 (1999-12-01), pages 260 - 267, XP001013538 * |
| GLINKA ET AL: "Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 391, no. 6665, 22 January 1998 (1998-01-22), pages 357 - 362, XP002096088, ISSN: 0028-0836 * |
| MORIN PJ: "beta-catenin signaling and cancer", BIOESSAYS, vol. 21, December 1999 (1999-12-01), pages 1021 - 1030, XP002174509 * |
| POLANEC J ET AL: "EFFECT OF WNT-1 ANTISENSE RNA ON THE OUTGROWTH OF A MAMMARY ADENOCARCINOMA CELL LINE EXPRESSING THAT ONCOGENE", JCP. CLINICAL MOLECULAR PATHOLOGY, LONDON, GB, vol. 49, no. 3, June 1996 (1996-06-01), pages 166 - 169, XP000929749, ISSN: 1355-2910 * |
| WODARZ A. AND NUSSE R.: "Mechanisms of Wnt signaling in development", ANN. REV. CELL DEVEL. BIOL., vol. 14, 1998, pages 59 - 88, XP001012698 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007090872A2 (fr) * | 2006-02-09 | 2007-08-16 | Novartis Ag | Agents de liaison de la proteine-4 apparentee a frizzled (sfrp-4) |
| WO2007090872A3 (fr) * | 2006-02-09 | 2007-11-29 | Novartis Ag | Agents de liaison de la proteine-4 apparentee a frizzled (sfrp-4) |
| EP2366432A1 (fr) | 2010-03-16 | 2011-09-21 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibiteurs de kinase 3 de synthèse de glycogène à utiliser dans les procédés thérapeutiques et procédé de criblage associé |
| WO2011113586A1 (fr) | 2010-03-16 | 2011-09-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibiteurs de la glycogène synthase kinase 3 destinés à être utilisés dans des méthodes thérapeutiques, et procédé de criblage associé |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1351711A2 (fr) | 2003-10-15 |
| US20040223952A1 (en) | 2004-11-11 |
| WO2002055109A3 (fr) | 2002-10-03 |
| CA2434431A1 (fr) | 2002-07-18 |
| WO2002055109A2 (fr) | 2002-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laurikkala et al. | Regulation of hair follicle development by the TNF signal ectodysplasin and its receptor Edar | |
| Zhang et al. | Gq activity-and β-arrestin-1 scaffolding-mediated ADGRG2/CFTR coupling are required for male fertility | |
| Litvin et al. | Expression and function of periostin‐isoforms in bone | |
| Weng et al. | Npas4 is a critical regulator of learning-induced plasticity at mossy fiber-CA3 synapses during contextual memory formation | |
| Shoval et al. | Antagonistic roles of full-length N-cadherin and its soluble BMP cleavage product in neural crest delamination | |
| Schaefer et al. | Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction | |
| Østbye et al. | The two myostatin genes of Atlantic salmon (Salmo salar) are expressed in a variety of tissues | |
| Knight et al. | Developmental expression analysis of the mouse and chick orthologues of IRF6: the gene mutated in Van der Woude syndrome | |
| Sun et al. | Expression of GDF-9, BMP-15 and their receptors in mammalian ovary follicles | |
| Johansson et al. | RAL GTPases drive intestinal stem cell function and regeneration through internalization of WNT signalosomes | |
| Ide et al. | In vivo evidence for an interplay of FGF23/Klotho/PTH axis on the phosphate handling in renal proximal tubules | |
| WO2006044486A2 (fr) | Methodes et compositions destinees a l'utilisation et au ciblage d'un osteomimetisme | |
| US20110020348A1 (en) | Pharmaceutical compositions and methods using secreted frizzled related protein | |
| EP1222933A1 (fr) | Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt | |
| Allgeier et al. | WNT5A selectively inhibits mouse ventral prostate development | |
| Shi et al. | TGF-β3-null mutation does not abrogate fetal lung maturation in vivo by glucocorticoids | |
| CZ2002903A3 (cs) | Farmaceutický prostředek s obsahem sekrenovaných proteinů příbuzných s proteiny frizzled | |
| JP6519851B2 (ja) | 眼細胞の分化マーカーおよび分化制御 | |
| Ma et al. | Hsal 1 is related to kidney and gonad development and is expressed in Wilms tumor | |
| WO2022137964A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies du cartilage/de l'os/des articulations, et procédé de criblage de médicament pour la prévention ou le traitement de maladies du cartilage/de l'os/des articulations | |
| Liegel et al. | Successful therapeutic intervention in new mouse models of frizzled 2-associated congenital malformations | |
| AU2002228458A1 (en) | Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway | |
| Liou et al. | Alternative splicing of the APC gene in the neural retina and retinal pigment epithelium | |
| US20220401515A1 (en) | Application of non-igf1r-binding substance in prevention and/or treatment of inflammatory diseases | |
| Rahman et al. | Canonical Wnt signaling regulates soft palate development by mediating ciliary homeostasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20020516 |